Brokerages Set Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target at $60.56
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one […]
More Stories
Trimedyne (OTCMKTS:TMED) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Shares of Trimedyne, Inc. (OTCMKTS:TMED – Get Free Report) crossed below its two hundred day moving average during trading on...
Trimedyne (OTCMKTS:TMED) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Shares of Trimedyne, Inc. (OTCMKTS:TMED – Get Free Report) crossed below its two hundred day moving average during trading on...
Trimedyne (OTCMKTS:TMED) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Shares of Trimedyne, Inc. (OTCMKTS:TMED – Get Free Report) crossed below its two hundred day moving average during trading on...
DoubleLine Income Solutions Fund (NYSE:DSL) Shares Pass Below 200-Day Moving Average – Should You Sell?
Shares of DoubleLine Income Solutions Fund (NYSE:DSL – Get Free Report) passed below its 200-day moving average during trading on...
DoubleLine Income Solutions Fund (NYSE:DSL) Shares Pass Below 200-Day Moving Average – Should You Sell?
Shares of DoubleLine Income Solutions Fund (NYSE:DSL – Get Free Report) passed below its 200-day moving average during trading on...
DoubleLine Income Solutions Fund (NYSE:DSL) Shares Pass Below 200-Day Moving Average – Should You Sell?
Shares of DoubleLine Income Solutions Fund (NYSE:DSL – Get Free Report) passed below its 200-day moving average during trading on...